小鼠脾臟中的巨噬細(xì)胞主要分為四種亞型:紅髓巨噬細(xì)胞(RPMs)、邊緣區(qū)巨噬細(xì)胞(MZM)、邊緣區(qū)金屬親和巨噬細(xì)胞(MMZM)和白髓可染體巨噬細(xì)胞。這四種亞型它們?cè)诙ㄎ?、功能和?biāo)志物上各具特征，共同維持血液穩(wěn)態(tài)與免疫防御?。而但在損傷或清除后，骨髓來源的單核細(xì)胞會(huì)迅速補(bǔ)充并分化為功能性巨噬細(xì)胞 。這種雙重來源機(jī)制保障了脾臟免疫功能的持續(xù)性。

當(dāng)使用荷蘭Liposoma氯膦酸鹽脂質(zhì)體Clodronate Liposomes尾靜脈注射后，清除效果通常在注射后24–48小時(shí)達(dá)到峰值 。氯膦酸鹽脂質(zhì)體Clodronate Liposomes主要清除吞噬能力強(qiáng)的邊緣區(qū)和紅髓巨噬細(xì)胞。因?yàn)槠⑴K巨噬細(xì)胞亞群復(fù)雜，且空間結(jié)構(gòu)和功能想對(duì)應(yīng)。清除的亞群以及亞群里面的結(jié)構(gòu)細(xì)分，更為精細(xì)。建議聯(lián)系靶點(diǎn)科技技術(shù)支持進(jìn)一步探討。脾臟巨噬細(xì)胞被清除后，骨髓來源的單核細(xì)胞會(huì)及時(shí)補(bǔ)充并分化為新的巨噬細(xì)胞?。新的巨噬細(xì)胞可在?1周內(nèi)左右開始重新出現(xiàn)?，并在后續(xù)幾天內(nèi)逐步恢復(fù)數(shù)量 。這些新補(bǔ)充的巨噬細(xì)胞在表型和功能上可能與原始脾臟巨噬細(xì)胞存在差異，通常表現(xiàn)為更強(qiáng)的促炎潛能或組織修復(fù)能力，具體取決于病理狀態(tài) 。

巨噬細(xì)胞清除劑Clodronateliposomes氯膦酸鹽脂質(zhì)體清除脾臟巨噬細(xì)胞效果時(shí)間動(dòng)態(tài)曲線-免疫組化，可以參考如下數(shù)據(jù)：

C.尾靜脈注射荷蘭Liposoma巨噬細(xì)胞清除劑ClodronateLiposomes（貨號(hào)：C-005），分別于注射后24h，48h，72h取樣脾臟，免疫組化（IHC）檢測(cè)脾臟F4/80，0h為注射的對(duì)照試劑ControlLiposomes（貨號(hào)：P-005）。注射后24h，約70%的F4/80陽性脾臟巨噬細(xì)胞被清除，注射后48h，約80%的F4/80陽性脾臟巨噬細(xì)胞被清除。注射后72h，開始有較大恢復(fù)。與肝臟對(duì)比，脾臟巨噬細(xì)胞清除后，恢復(fù)速度快于肝臟。當(dāng)然，脾臟的巨噬細(xì)胞亞群比肝臟復(fù)雜的多，恢復(fù)的亞群值得研究。

D.免疫組化染色F4/80陽性區(qū)域占比脾臟的百分比。

論文信息：

論文題目：Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice

期刊名稱：Science Advances

時(shí)間期卷：Vol 11, Issue 13(2025)

在線時(shí)間：2025年3月26日

DOI：10.1126/sciadv.ads2295

產(chǎn)品信息：

貨號(hào)：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes&Control Liposomes

辦事處：靶點(diǎn)科技

Clodronate Liposomes氯膦酸鹽脂質(zhì)體在小鼠創(chuàng)傷性脊髓損傷（SCI）模型種清除肝臟和脾臟巨噬細(xì)胞。荷蘭Liposoma巨噬細(xì)胞清除劑ClodronateLiposomes見刊于Science Advances：巨噬細(xì)胞靶向的Mms6 mRNA脂質(zhì)納米顆粒促進(jìn)小鼠創(chuàng)傷性脊髓損傷后的運(yùn)動(dòng)功能恢復(fù)

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體清除巨噬細(xì)胞的材料和方法：

Macrophage depletion and evaluation of depletion efficiency

Macrophages were depleted by injection of clodronate-contained liposomes (Clodrosome) into mice (Liposoma B.V., Amsterdam, The Netherlands) according to a previously published protocol (40). C57BL/6J mice were intravenously injected with 0.2 ml of Clodrosome (5 mg/ml). Mice treated with PBS-containing liposomes without clodronate were used as controls. Flow cytometry and immunohistochemistry were used to assess the efficiency of macrophage depletion in the liver and spleen of mice at 0, 24, 48, and 72 hours after Clodrosome treatment using a mouse anti-F4/80 antibody (ab111101, Abcam; 1:100). Then, the optimal timing of maximum depletion was chosen for further study.

巨噬細(xì)胞清除材料和方法文獻(xiàn)截圖：